Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.62 |
| ▸ | CTSS | P25774 | 5/20 | 0.62 |
| ▸ | SYK | P43405 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 6/20 | 0.53 |
| ▸ | CTSB | P07858 | 4/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 2/20 | 0.48 |
| ▸ | ECE1 | P42892 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7286508 | 1.00 | CTSL (0.62) | CTSLCTSSSYKCTSKCTSB | |
| SCHEMBL2679219 | 1.00 | CTSL (0.62) | CTSLCTSSSYKCTSKCTSB | |
| SCHEMBL11657615 | 0.91 | SYK (0.59) | CTSLCTSSSYKCTSKCTSB | |
| SCHEMBL20885259 | 0.91 | SYK (0.59) | CTSLCTSSSYKCTSKCTSB | |
| SCHEMBL13827783 | 0.90 | CTSS (0.56) | CTSLCTSSSYKCTSKCTSB | |
| SCHEMBL6181712 | 0.90 | CTSS (0.56) | CTSLCTSSSYKCTSKCTSB | |
| SCHEMBL3133278 | 0.90 | CTSS (0.56) | CTSLCTSSSYKCTSKCTSB | |
| SCHEMBL20993818 | 0.90 | CTSS (0.56) | CTSLCTSSSYKCTSKCTSB | |
| SCHEMBL16488769 | 0.90 | CTSS (0.56) | CTSLCTSSSYKCTSKCTSB | |
| SCHEMBL3133276 | 0.90 | CTSS (0.56) | CTSLCTSSSYKCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4660303-A2 | PCSK9 ANTAGONIST COMPOUNDS | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-3810626-B1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250206781-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-06-26 | — | — | US | disclosed |
| US-12209145-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2025-01-28 | — | — | US | disclosed |
| US-12178842-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2024-12-31 | — | — | US | disclosed |
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-06-01 | — | — | US | disclosed |
| US-20230159592-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-05-25 | — | — | US | disclosed |
| WO-2023044171-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-03-23 | — | — | WO | disclosed |
| US-11484565-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2022-11-01 | — | — | US | disclosed |
| US-11427616-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2022-08-30 | — | — | US | disclosed |
| US-8188311-B2 | L-threonine derivatives of high therapeutic index | SIGNATURE R&D HOLDINGS, LLC (US) | 2012-05-29 | — | — | US | disclosed |
| US-8173840-B2 | Compounds with high therapeutic index | SIGNATURE R&D HOLDINGS, LLC (US) | 2012-05-08 | — | — | US | disclosed |
| US-20110212078-A1 | SYNTHESIS AND USE OF HETEROCYCLIC ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME CORP. | 2011-09-01 | — | — | US | disclosed |
| US-20100069446-A1 | L-THREONINE DERIVATIVES OF HIGH THERAPEUTIC INDEX | SIGNATURE R&D HOLDINGS (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069489-A1 | L-THREONINE DERIVATIVES OF HIGH THERAPEUTIC INDEX | SIGNATURE R&D HOLDINGS (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100004481-A1 | L-THREONINE DERIVATIVES OF HIGH THERAPEUTIC INDEX | SIGNATURE R&D HOLDINGS (US) | 2010-01-07 | — | — | US | disclosed |
| US-7589233-B2 | L-Threonine derivatives of high therapeutic index | SIGNATURE R&D HOLDINGS, LLC (US) | 2009-09-15 | — | — | US | disclosed |
| WO-2007089745-A2 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX | SIGNATURE R & D HOLDINGS, LLC (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20060287244-A1 | L-Threonine derivatives of high therapeutic index | SIGNATURE R&D HOLDINGS, LLC | 2006-12-21 | — | — | US | disclosed |
| US-20060241017-A1 | Novel compounds with high therapeutic index | SIGNATURE R&D HOLDINGS, LLC | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | CTSL 213/4885CTSS 287/4885SYK 2553/4885 |
| US-20230159592-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | CTSL 506/4885CTSS 578/4885SYK 2134/4885 |
| US-20100069446-A1 | L-THREONINE DERIVATIVES OF HIGH THERAPEUTIC INDEX | BCAT1, AADAT, TPI1 | CTSL 1058/4885CTSS 3079/4885SYK 2697/4885 |
| US-12178842-B2 | PCSK9 antagonist compounds | PCSK9, PCSK7, PCSK6 | CTSL 213/4885CTSS 287/4885SYK 2553/4885 |
| US-20100004481-A1 | L-THREONINE DERIVATIVES OF HIGH THERAPEUTIC INDEX | BCAT1, AADAT, TPI1 | CTSL 1058/4885CTSS 3079/4885SYK 2697/4885 |
| US-20110212078-A1 | SYNTHESIS AND USE OF HETEROCYCLIC ANTIBACTERIAL AGENTS | LPXN, LSS, NISCH | CTSL 1882/4885CTSS 1316/4885SYK 3717/4885 |
| US-11427616-B2 | PCSK9 antagonist compounds | PCSK9, PCSK7, PCSK6 | CTSL 506/4885CTSS 578/4885SYK 2134/4885 |
| US-12209145-B2 | PCSK9 antagonist compounds | PCSK9, PCSK7, PCSK6 | CTSL 506/4885CTSS 578/4885SYK 2134/4885 |
| US-20060287244-A1 | L-Threonine derivatives of high therapeutic index | BCAT1, AADAT, TPI1 | CTSL 1058/4885CTSS 3079/4885SYK 2697/4885 |
| US-11484565-B2 | PCSK9 antagonist compounds | PCSK9, PCSK7, PCSK6 | CTSL 213/4885CTSS 287/4885SYK 2553/4885 |
| US-20250206781-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | CTSL 506/4885CTSS 578/4885SYK 2134/4885 |
| US-20060241017-A1 | Novel compounds with high therapeutic index | IL4I1, SLC7A1, GOT1 | CTSL 245/4885CTSS 536/4885SYK 4600/4885 |
| US-20100069489-A1 | L-THREONINE DERIVATIVES OF HIGH THERAPEUTIC INDEX | BCAT1, AADAT, TPI1 | CTSL 1058/4885CTSS 3079/4885SYK 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.